Therapeutic targeting LRPPRC-mediated OXPHOS synthesis for cancer intervention
Current LRPPRC inhibitors often suffer from suboptimal specificity and binding affinity. Advancing clinical translation requires co-crystal structures of LRPPRC for rational drug design and novel delivery strategies to enhance mitochondrial enrichment of inhibitors.
Authors
- Dachi Wang (ORCID: https://orcid.org/0009-0008-7535-8564)
- L. Wang
- Wenxi Wang (ORCID: https://orcid.org/0009-0008-4225-3969)
- Xiaohong Fang (ORCID: https://orcid.org/0000-0001-5388-7416)
- Ruibin Jiang (ORCID: https://orcid.org/0000-0002-3816-4639)
- Wenjia Chen
- Yuxin Liang
- Wei Zhou
- Ziyan Yang
Institutions
- Chinese Academy of Sciences (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Expert Opinion on Therapeutic Targets
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/14728222.2025.2608028
- Citations
- 1
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.81